Literature DB >> 16567077

The role of salvage surgery for recurrence of esophageal squamous cell cancer.

S Natsugoe1, H Okumura, M Matsumoto, Y Uchikado, T Setoyama, Y Uenosono, S Ishigami, T Owaki, T Aikou.   

Abstract

AIM: A consensus treatment strategy for recurrent esophageal squamous cell cancer (ESCC) has not been established. The purpose of the present study was to analyse the mode of recurrence, and evaluate the role of surgical salvage treatment in recurrence of ESCC.
METHODS: Recurrence was detected in 131 of 367 consecutive patients with ESCC. We retrospectively analysed the mode of recurrence and treatment for recurrence. Recurrence was divided into four types; lymph node, hematogeneous, mixed and local. Treatments were classified into four groups; chemotherapy alone (C group), radiation therapy +/- chemotherapy (R group), surgery +/- other therapy (S group), and no therapy (N group).
RESULTS: Of the 131 recurrences, the number of patients with lymph node, hematogeneous, mixed and local recurrence was 43, 44, 40 and 4, respectively. The number of patients in the C, R, S, N groups was 35, 35, 24 and 37, respectively. Of the 24 patients who received surgical treatment for recurrence, the number of patients with lymph node, hematogeneous, mixed and local recurrence was 11, 6, 6 and 1, respectively. The number of lesions in hematogeneous recurrence was 2 or less. The survival rate from recurrence to death in the C, R, S and N groups was 0, 3.9, 6.7 and 0%, respectively. A statistically significant difference was found in these groups (p < 0.0001).
CONCLUSIONS: Salvage surgery is one of the useful treatment tools for resectable metastatic lesions. In such cases, the number of lesions, recurrent sites and effectiveness of chemotherapy and/or radiotherapy should be carefully evaluated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567077     DOI: 10.1016/j.ejso.2006.02.014

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  16 in total

1.  Patterns and time of recurrence after complete resection of esophageal cancer.

Authors:  Masahiko Sugiyama; Masaru Morita; Rintaro Yoshida; Koji Ando; Akinori Egashira; Ohga Takefumi; Hiroshi Saeki; Eiji Oki; Yoshihiro Kakeji; Yoshihisa Sakaguchi; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-02-28       Impact factor: 2.549

2.  Clinical course and outcome after esophagectomy with three-field lymphadenectomy in esophageal cancer.

Authors:  Shoji Natsugoe; Masataka Matsumoto; Hiroshi Okumura; Yasuto Uchikado; Tetsuro Setoyama; Ken Sasaki; Toshihide Sakurai; Itaru Omoto; Tetsuhiro Owaki; Hiroyuki Shinchi; Shinichi Ueno; Sumiya Ishigami
Journal:  Langenbecks Arch Surg       Date:  2010-02-21       Impact factor: 3.445

3.  18FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma.

Authors:  Sonia L Betancourt Cuellar; Diana P Palacio; Carol C Wu; Brett W Carter; Arlene M Correa; Wayne L Hofstetter; Edith M Marom
Journal:  Br J Radiol       Date:  2017-11-28       Impact factor: 3.039

4.  Patterns and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy.

Authors:  Kotaro Yamashita; Masayuki Watanabe; Shinji Mine; Takanori Kurogochi; Akihiko Okamura; Masaru Hayami; Yu Imamura
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

5.  Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.

Authors:  Punit Sharma; Sachin Jain; Sellam Karunanithi; Sujoy Pal; Pramod Kumar Julka; Sanjay Thulkar; Arun Malhotra; Chandrasekhar Bal; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

6.  Salvage lymphadenectomy for recurrent esophageal cancer after chemoradiotherapy.

Authors:  Masanobu Nakajima; Yasushi Domeki; Hitoshi Satomura; Masakazu Takahashi; Akira Sugawara; Hiroto Muroi; Kinro Sasaki; Satoru Yamaguchi; Tatsuya Miyazaki; Hiroyuki Kuwano; Hiroyuki Kato
Journal:  Int Surg       Date:  2014 Jul-Aug

7.  Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer.

Authors:  Sumiya Ishigami; Shoji Natsugoe; Akihiro Nakajo; Masataka Matsumoto; Yoshikazu Uenosono; Takaaki Arigami; Tetsuro Setoyama; Hideo Arima; Yasuto Uchikado; Yoshiaki Kita; Ken Sasaki; Takashi Aikou
Journal:  J Gastrointest Surg       Date:  2008-05-31       Impact factor: 3.452

8.  Comparison between different reconstruction routes in esophageal squamous cell carcinoma.

Authors:  Yu-Zhen Zheng; Shu-Qin Dai; Wei Li; Xun Cao; Xin Wang; Jian-Hua Fu; Peng Lin; Lan-Jun Zhang; Bin Lu; Jun-Ye Wang
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

9.  Use of positron emission tomography in surgery follow-up of esophageal cancer.

Authors:  P Teyton; J P Metges; A Atmani; V Jestin-Le Tallec; A Volant; D Visvikis; J P Bail; O Pradier; P Lozac'h; Catherine Cheze Le Rest
Journal:  J Gastrointest Surg       Date:  2008-11-21       Impact factor: 3.452

10.  Esophageal gel-shifting technique facilitating eradicative boost or reirradiation to upper mediastinal targets of recurrent nerve lymph node without damaging esophagus.

Authors:  Kazushi Kishi; Takeshi Iida; Toshiyasu Ojima; Tetsuo Sonomura; Shintaro Shirai; Motoki Nakai; Morio Sato; Hiroki Yamaue
Journal:  J Radiat Res       Date:  2013-02-21       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.